These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34616675)

  • 1. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
    Brasó-Maristany F; Sansó M; Chic N; Martínez D; González-Farré B; Sanfeliu E; Ghiglione L; Carcelero E; Garcia-Corbacho J; Sánchez M; Soy D; Jares P; Peg V; Saura C; Muñoz M; Prat A; Vivancos A
    Front Oncol; 2021; 11():710596. PubMed ID: 34616675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
    Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
    J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
    Kagihara JA; Andress M; Diamond JR
    Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
    Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
    Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
    Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab for the treatment of triple-negative breast cancer.
    Heimes AS; Schmidt M
    Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
    Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
    Front Oncol; 2022; 12():779786. PubMed ID: 35646659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab for the treatment of breast cancer.
    Reddy SM; Carroll E; Nanda R
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.
    Wu B; Ma F
    Ther Adv Med Oncol; 2020; 12():1758835920916000. PubMed ID: 32426048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
    Chumsri S; Sokol ES; Soyano-Muller AE; Parrondo RD; Reynolds GA; Nassar A; Thompson EA
    J Natl Compr Canc Netw; 2020 May; 18(5):517-521. PubMed ID: 32380464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer.
    Baek SH; Kim JH; Bae SJ; Ji JH; Lee Y; Jeong J; Cha YJ; Ahn SG
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer.
    Zhao H; Ma W; Fragoso RC; Iv GRH; Ashok A; Li T
    J Natl Cancer Cent; 2021 Sep; 1(3):115-121. PubMed ID: 39036375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer.
    Simmons CE; Brezden-Masley C; McCarthy J; McLeod D; Joy AA
    Ther Adv Med Oncol; 2020; 12():1758835920909091. PubMed ID: 33014143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
    Blackley EF; Loi S
    Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.
    Ou-Yang F; Li CL; Chen CC; Shen YC; Moi SH; Luo CW; Xia WY; Wang YN; Lee HH; Wang LH; Wang SC; Pan MR; Hou MF; Hung MC
    Am J Cancer Res; 2022; 12(1):123-137. PubMed ID: 35141008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.